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Antidepressants and suicide
Treatment is probably too sporadic to affect overall suicide rates
Two accompanying observational studies by Biddle 
and colleagues and Wheeler and colleagues add to 
the recent literature regarding changes in antidepres-
sant use and changes in suicide rates.1 2 The current 
controversy began in 2003, when reanalyses of data 
from clinical trials raised concerns that antidepressants 
might precipitate suicidal thoughts or attempts at sui-
cide. Children and adolescents starting treatment with 
several newer antidepressants had a 4% risk of devel-
oping suicidal ideation or behaviour, compared with 
2% in those receiving placebo.3 However, clinical trials 
cannot determine whether antidepressants increase or 
decrease the risk of genuine suicide attempts or death 
from suicide because these outcomes are, fortunately, 
too rare. No deaths from suicide and few attempts at 
suicide have occurred to date in trials of antidepres-
sants in adolescents,3 so any clinical trial that could 
reliably assess effects on death from suicide would 
require several times more participants than have been 
included in all such trials to date.
Any study of serious suicide attempts or death from 
suicide must fall back on observational analyses of data 
from large populations. What population based stud-
ies gain in sample size, however, they lose in ability to 
account for bias or confounding. For example, if we 
simply compare suicide rates between people who are 
using and not using antidepressants, we would erro-
neously conclude that antidepressants increase risk. 
That conclusion would ignore the fact that symptoms 
of depression (including suicidal ideation) are the 
reason that antidepressants are prescribed. Although 
more sophisticated observational studies try to account 
for bias or confounding, they are never as good as 
randomised trials.
Bearing in mind these limitations, several obser-
vational studies have suggested that antidepressants 
might actually reduce the risk of attempted suicide or 
death from suicide. In adolescents and adults, the risk 
of suicide declines sharply after starting treatment with 
antidepressants.4 Areas with higher rates of antidepres-
sant prescribing tend to have lower suicide rates.5 As 
the use of antidepressants in adolescents increased in 
the United States between 1990 and 2003, suicide rates 
declined. And when warnings led to decreased anti-
depressant use between 2003 and 2004, the suicide 
rate in US adolescents increased for the first time in 
a decade.6
More recent observational studies, however, raise 
doubts about an association between suicide rates and 
changes in antidepressant prescribing. The most recent 
US data suggest that adolescent suicide deaths began 
to decrease again between 2004 and 2005.7 The two 
accompanying observational studies show a lack of 
connection between antidepressant prescribing rates 
and suicide rates in adolescents and young adults in 
the United Kingdom.1 2 Suicide rates declined when 
antidepressant use steadily increased but continued to 
decline when the use of antidepressants fell sharply in 
2003 and 2004.
In truth, it would be surprising if antidepressants 
had any effect—positive or negative—on the risk of sui-
cide in the general population. In the US, only half of 
adults and a quarter of adolescents who have a major 
episode of depression in any given year start taking 
an antidepressant.8 Nearly half of all adults who start 
treatment discontinue after just a few weeks.9 Only 
3% of adolescents dying by suicide in New York City 
had toxicology data showing recent use of antidepres-
sants.10 Sustained use of antidepressants is probably 
too rare to have much overall effect on risk of suicide 
in people living with depression.
The shifting association between antidepressant pre-
scribing rates and suicide rates argues for caution in 
interpreting other ecological associations. Although we 
can see that changes in suicide mortality are associated 
with changes in social conditions or population rates 
of substance use, ecological associations do not imply 
causality. We tend to search for or believe only those 
associations that fit in with our expectations.
Observational data do clearly show that warnings 
in the UK and the US reduced rates of antidepressant 
prescribing, especially in adolescents. Between 2003 
and 2005, antidepressant use in adolescents declined 
by about 20% in the US, 30% in the Netherlands, and 
40% in the UK.1 2 6
Unfortunately, we can find no evidence that regula-
tors’ urgent recommendations for closer monitoring 
of treatment led to any improvement in practice. The 
US Food and Drug Administration urges weekly or 
biweekly follow-up after starting antidepressant treat-
ment. National quality measures in the US indicate 
that only a fifth of patients starting antidepressants 
have even three follow-up visits over three months.9 
Furthermore, follow-up rates have shown no improve-
ment over the past five years. We can only hope that 
regulatory warnings will eventually have as much effect 
on the quality of treatment as on the quantity.
Biddle L, Brock A, Brookes ST, Gunnell D. Suicide rates in young men 1 
in England and Wales in the 21st century: time trend study. BMJ 2008 
doi: 10.1136/bmj.39475.603935.25.
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Efficacy of antidepressants
is not an absolute measure, and it depends on how clinical significance is defined
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In February 2008, Kirsch and colleagues reported a 
meta-analysis of the efficacy of antidepressants using 
data from clinical trials submitted to the Food and 
Drug Administration.1 They provocatively concluded, 
“there seems little evidence to support the prescrip-
tion of antidepressant medication to any but the most 
severely depressed patients.”
In January this year, we published an article about 
the selective publication of antidepressant trials and its 
influence on apparent efficacy,2 in which we also used 
FDA data. Our main finding was that antidepressant 
drugs are much less effective than is apparent from 
journal articles. From the FDA data we derived an 
overall effect size of 0.31. Kirsch and colleagues used 
FDA data from four of the 12 drugs we examined and 
calculated an overall effect size of 0.32.
Although these two sets of results were in excellent 
agreement, our interpretations of them were quite dif-
ferent. In contrast to Kirsch and colleagues’ conclusion 
that antidepressants are ineffective, we concluded that 
each drug was superior to placebo. The difference in 
our interpretations stems from Kirsch and colleagues’ 
use of the criteria for clinical significance recommended 
by the UK’s National Institute for Health and Clinical 
Excellence (NICE).
Clinical significance is an important concept because 
a clinical trial can show superiority of a drug to pla-
cebo in a way that is statistically, but not clinically, 
significant. Tests of statistical significance give a yes or 
no answer (for example, P<0.05 is deemed significant, 
P>0.05 non-significant) that tells us whether the true 
effect size is zero or not, but it tells us nothing about the 
size of the effect.3 In contrast, effect size does, and thus 
allows us to look at the question of clinical significance. 
Values of 0.2, 0.5, and 0.8 were proposed to represent 
small, medium, and large effects, respectively.4
NICE chose the “medium” value of 0.5 as a cut-off 
below which they deem benefit of a drug not clini-
cally significant.5 This is problematic because it trans-
forms effect size, a continuous measure, into a yes or 
no measure, thereby suggesting that drug efficacy is 
either totally present or absent, even when comparing 
values as close together as 0.51 and 0.49. Kirsch and 
colleagues compared their effect size of 0.32 to the 0.50 
cut-off and concluded that the benefits of antidepres-
sant drugs were of no clinical significance.
But on what basis did NICE adopt the 0.5 value 
as a cut-off? When Cohen first proposed these land-
mark effect size values, he wrote, “The terms ‘small’, 
‘medium’, and ‘large’ are relative . . . to each other . . . 
the definitions are arbitrary . . . these proposed conven-
tions were set forth throughout with much diffidence, 
qualifications, and invitations not to employ them if pos-
sible.” He also said, “The values chosen had no more 
reliable a basis than my own intuition.” Thus, it seems 
doubtful that he would have endorsed NICE’s use of an 
effect size of 0.5 as a litmus test for drug efficacy.
To illustrate Cohen’s use of “relative” with a metaphor, 
imagine antidepressant efficacy measured in terms of 
litres of a fluid called “d-juice” (named after Cohen’s “d”—
the effect size measure described here). When our group 
measured 0.41 litres of d-juice in the “glass” represent-
ing journal articles, but 0.31 litres in the FDA glass, we 
concluded that the FDA glass was empty relative to the 
journal glass. Nevertheless, we acknowledged that 0.31 
litres was an amount that was measurable and significant. 
Kirsch and colleagues measured 0.32 litres of d-juice, 
but because they did not consider the glass sufficiently 
full (defined arbitrarily as P≥0.5), they concluded that 
the glass contained virtually no d-juice whatsoever. To 
summarise, we agree that the antidepressant “glass” is far 
from full, but we disagree that it is completely empty.
Hypothetically, if antidepressants are not worth taking, 
then what should doctors and patients do? Kirsch and 
colleagues recommend that if antidepressants are to be 
used at all they should be used only when alternative 
treatments have failed to provide a benefit.1 Although the 
authors did not specify a preferred first line treatment, 
they may have had psychotherapy in mind.6 7 It seems 
unfair that pharmacological, and not psychotherapeutic, 
treatment has become the usual first line approach to 
depression merely for economic reasons.7 But before 
we embrace any treatment as first line, it is prudent to 
ask whether its efficacy is beyond question. For psycho-
therapy trials, there is no equivalent of the FDA whose 
records we can examine, so how can we be sure that 
selective publication is not occurring here as well?
Our clinical recommendation is that when 
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Acupuncture with in vitro fertilisation
May increase birth rates, but guidelines should await the results of ongoing trials
According to the European Society of Human Repro-
duction and Embryology, more than 300 000 treatment 
cycles of in vitro fertilisation and intracytoplasmatic 
sperm injection are performed each year in Europe.1 
Because in vitro fertilisation can affect physical and men-
tal health, professionals delivering this treatment are try-
ing to optimise the technology to increase birth rates.
About 90% of all assisted reproductive treatment 
cycles result in the transfer of at least one embryo, but 
only about 25% of all cycles end in implantation of the 
embryo and live birth. The main factor limiting the 
success of treatment is failure of implantation and not 
the lack of human embryos for transfer. Initiatives to 
improve rates of implantation have had varying success. 
In the accompanying systematic review,  Manheimer 
and colleagues report improved pregnancy rates with 
in vitro fertilisation when acupuncture accompanies 
embryo transfer.2
As far as we are aware, this is the first systematic 
review and meta-analysis of the success rates of in vitro 
fertilisation with adjuvant acupuncture. It included 
seven methodologically sound randomised control-
led trials with little clinical heterogeneity that studied 
1366 women having in vitro fertilisation between 2002 
and 2006. Adjuvant acupuncture at the time of embryo 
transfer significantly increased the rates of clinical preg-
nancy (odds ratio 1.65, 95% confidence interval 1.40 
to 2.49) and live birth (1.91, 1.39 to 2.64). The number 
needed to treat with adjuvant acupuncture to achieve 
one more pregnancy was 10 and to obtain one more 
live birth this number was nine. A subgroup analysis 
restricted to the three studies with highest clinical preg-
nancy rates in the control groups, however, found no 
significant benefit of acupuncture (1.24, 0.86 to 1.77).
The pooled odds ratios on pregnancy rates after in 
vitro fertilisation with adjuvant acupuncture are higher 
than reported odds ratios for drugs or other procedures 
given to enhance the success of this treatment. For 
example, gonadotrophin preparations with luteinis-
ing hormone activity versus preparations without such 
activity gave a relative risk of clinical pregnancy of 
1.17 (1.03 to 1.34)3; the use of assisted hatching (which 
prepares the embryos before transfer) gave an odds 
ratio of clinical pregnancy of 1.63 (1.27 to 2.09)4; and 
transfer of day 5 embryos (blastocyst stage) versus day 
3 embryos (cleavage stage) gave an odds ratio for clini-
cal pregnancy of 1.27 (1.03 to 1.55).5
Manheimer and colleagues have extensively dealt 
with and discussed the limitations of their meta-analy-
sis and the possibility of biased results. We consider the 
results to be just as solid as any other meta-analysis of 
adjuvant treatment or medical procedures in assisted 
reproduction. However, although meta-analyses pro-
vide the highest level of scientific evidence, caution 
should be used when using data from small meta-
analyses with a risk of publication bias to make daily 
clinical decisions.
The current meta-analysis was based on seven ran-
domised controlled trials, and only three relatively 
small trials included a sham control group. Results of 
meta-analyses should always be interpreted in terms of 
how biologically plausible they are. In this instance, the 
biological mechanism is difficult to explain. Adjuvant 
acupuncture was given immediately before or immedi-
ately after embryo transfer. The effects of acupuncture 
are therefore most likely to involve uterine contrac-
tility rather than uterine receptivity. Acupuncture is 
unlikely to have exerted a central effect by mediating 
the release of neurotransmitters because the hypotha-
lamic secretion of gonadotrophin releasing hormone 
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 considering the potential benefits of treatment with 
antidepressants, be circumspect but not  dismissive. 
Efficacy measured in clinical trials does not 
 necessarily translate into effectiveness in  clinical 
practice.8 Patients’ individual responses are like 
clinical trial effect sizes in that they are not all or 
none. Thus, when a patient is tried on his or her 
first  antidepressant, a partial response should not be 
surprising or  discouraging. Also, depression rating 
scales used in clinical trials seldom measure quality 
of life, which has been suggested to be a reasonable 
measure of clinical significance.9
With regard to policy, we reiterate our request 
in 2004 for drug regulatory authorities such as the 
FDA to make their reviews publicly available on 
the world wide web—retrospectively.10 Making this 
 unbiased information more accessible will allow 
other  researchers to move beyond antidepressants and 
ascertain the true efficacy of all marketed drugs.
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would be “switched off” by the gonadotrophin releasing 
hormone analogues used during in vitro fertilisation 
and the high levels of oestradiol. Acupuncture may act 
by reducing the contractility of the uterus and thereby 
avoiding expulsion of embryos after transfer or through 
unknown effects on the blood flow to the endometrium.6 
Animal and human studies investigating the effect of 
acupuncture through a direct or indirect mechanism on 
the uterus or the endometrium are needed.
National guidelines and recommendations should be 
based on systematic reviews and meta-analyses. Should 
adjuvant acupuncture now be included in national guide-
lines such as the National Institute for Health and Clinical 
Excellence guidelines from the British Fertility Society?7 
We think that it is too early for such a recommenda-
tion. Publication bias may have influenced the results 
of the meta-analysis. A Danish randomised controlled 
trial on adjuvant acupuncture that includes more than 
600 women having in vitro fertilisation (twice as many 
as in the largest randomised controlled trial included in 
the meta-analysis) is currently under way. Before  adding 
 adjuvant acupuncture for in vitro fertilisation to any 
national guideline we must wait for the results of this and 
other studies to clarify the value of this treatment.
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Funding for primary health care in developing countries
Money from disease specific projects could be used to strengthen primary care 
The World Health Organization’s World Health Report 
2007 deals with access to primary health care as an 
essential prerequisite for health.1 It acknowledges the 
importance of the Alma-Ata declaration of 1978, which 
called for integrated primary health care as a way to 
deal with major health problems in communities and 
for access to care as part of a comprehensive national 
health system. Yet the mission of Alma-Ata—to provide 
accessible, affordable, and sustainable primary health 
care for all—has been implemented only partially in 
developing countries.2 We have therefore instigated 
the “15by2015” campaign (www.15by2015.org), which 
proposes a funding mechanism for strengthening pri-
mary health care in developing countries.
In the accompanying analysis article, Gillam notes 
that most developing countries have failed to provide 
even basic primary healthcare packages. Weaknesses 
in primary healthcare services often result from a vari-
ety of forces, including economic crises and market 
reforms, which limit the range and coverage of services 
and thus their effect on health.3 4 On the positive side, 
between 1997 and 2002, financial support to improve 
health care in developing countries increased by about 
26%, from $6.4bn (£3.3m; €4.4m) to $8.1bn.5 How-
ever, most aid was allocated to disease specific projects 
(termed “vertical programming”) rather than to broad 
based investments in health infrastructure, human 
resources, and community oriented primary healthcare 
services (“horizontal programming”).6
An example of vertical programming is the enormous 
donor response to the HIV epidemic. In 2006, although 
Zambia’s entire Ministry of Health budget was only 
$136m, the President’s Emergency Plan for AIDS Relief 
provided the country with an HIV targeted budget of 
$150m. This unbalanced distribution of health funding 
occurs across sub-Saharan Africa. Thus, although HIV 
positive patients receive free care, others with more rou-
tine diseases receive poor care and still have to pay. Sala-
ries of healthcare providers working for donor funded 
vertical programmes are often more than double those 
of equally trained government workers in the fragile 
public health sector. This lures government workers to 
the higher paying vertical programmes and creates an 
internal “brain drain.” But it is the underfunded primary 
care clinics and health centres that care for all diseases, 
including common illnesses such as diarrhoea, malnutri-
tion, and respiratory tract infections, which take many 
more lives than HIV, tuberculosis, and malaria.
A new global strategy is needed to reinforce commu-
nity focused primary health care in developing coun-
tries. This will require cooperation between ministries, 
universities, non-governmental organisations, and 
donors working on health to overcome severe resource 
constraints, including insufficient numbers of doctors, 
pharmacists, and other health personnel. Four interna-
tional organisations—the World Organization of Family 
Doctors (www.globalfamilydoctor.com); Global Health 
through Education, Training and Service (www.ghets.
org); the Network: Towards Unity for Health (www.
the-networktufh.org); and the European Forum for Pri-
mary Care (www.euprimarycare.org )—have therefore 
set up the 15by2015 campaign to foster a better balance 
between vertical and horizontal aid. This campaign 
calls for major international donors to assign 15% of 
their vertical budgets by 2015 to strengthening horizon-
tal primary healthcare systems so that all diseases can 
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be prevented and treated in a systematic way.
This campaign is not acting in a vacuum. A broad 
approach—orienting funds to governments for com-
prehensive provision of care—is being implemented in 
several countries in sub-Saharan Africa. The Global 
Fund to fight AIDS, Tuberculosis, and Malaria has 
called for investment to strengthen health systems and 
tackle social determinants by supporting strategies to 
reduce poverty.7 The United Kingdom’s prime minister, 
 Gordon Brown, in a joint statement with Germany’s 
chancellor, Angela Merkel, announced the launch of 
the “International Health Partnership.”8 The core idea 
is to encourage low income countries to create compre-
hensive country-wide health programmes, which would 
serve as the basis for all foreign assistance for health. 
Hopefully, other donors will follow these leads.
How would 15by2015 work? Take the example of 
Mozambique. In 2005, the total health expenditure in 
the country was $356m. Foreign assistance accounted 
for $243m, from which $130m was channelled through 
disease specific vertical funds managed directly by 
donors.9 We propose that, 15% of the vertical funds from 
donor organisations (in this example, $19.5m) should 
be diverted into the government’s common health fund 
and be earmarked for strengthening primary health 
care through improvement of infrastructure, health 
education, and investment in human resources. This 
amount of money could support 65 health centres for 
a year. These centres could be staffed by primary care 
teams  including family doctors, mid-level care workers, 
 primary care nurses, pharmacists, and health promoters. 
If one  primary healthcare centre covers a population of 
20 000 people, then 65 health centres would give 1.3 
million people access to improved primary health care.
Part of the 15by2015 fund could be allocated to sup-
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Recently, the Department of Work and Pensions in 
the United Kingdom announced a renewal of the per-
sonal capacity assessment. The report states that the 
renewal is expected to result in 20 000 fewer people 
claiming sickness benefits each year. It also claims that 
the new test is more robust, accurate, and fair than the 
 previous one.1
Two issues are at stake here: firstly, the provision of 
work and a decent income for millions of people with 
disabilities and, secondly, the billions of pounds that 
society is willing and able to pay in disability benefits. 
In many European countries, the growing numbers of 
 people claiming disability benefit and expenditure on 
these benefits is an important point of political interest.2
The personal capacity assessment lists 17 activities, 
each of which can be given a score according to the 
degree of limitation. People with a score of 15 or more 
are assessed as unable to work. Changes have been 
made to the 17 activities and limitations in the new 
assessment; for example, not being able to walk more 
than 30 metres had the highest disability score in the 
old assessment but this has been changed to 50 metres 
in the new one. Other changes make it more difficult 
to reach the highest level of work disability.
It is generally agreed that the World Health Organi-
zation (WHO) model of functioning provides the best 
framework for the evaluation of disability.3 The basis of 
this model is that disability has three major components 
apart from having a disease: impairments in bodily or 
mental functions or structures, limitations in activi-
ties, and restrictions in participation in societal roles. 
 Personal and environmental factors also play a role.
It is important for doctors to understand the essential 
difference between having a disease and having a dis-
ability.4 The ability to work depends on balancing the 
limitations in activities with the demands that partici-
pation in working life imposes. The personal capacity 
assessment does reflect the WHO model in that the 
port the training and upgrading of skills. It could also 
be used to provide better pay for health personnel to 
encourage them to stay in areas where they are needed 
and to pay for community health workers, mid-level 
care workers, and “African family physicians” who are a 
fledgling but emerging force.10 11 The Ministry of Health 
should monitor the accessibility and quality of this care 
in a transparent way to ensure that the 15by2015 fund is 
used most effectively to improve community health.
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test items refer to limitations in activities and the cut-
off scores refer to the demands that work in general 
imposes on us. The cut-off score provides an indication 
of the severity of the limitations.
The new test claims to be fair and accurate, but the 
report does not define what this means. The test was 
evaluated against expert opinion in 212 cases. Even 
though essential qualifiers like sensitivity and specificity 
of the test are not reported, it is implied that specificity 
is higher and sensitivity is lower in the new test. Instead 
of referring to the usual trade-off between specificity 
and sensitivity, the authors of the report argue that 
the decrease in sensitivity occurred by chance. This is 
important because a decrease in sensitivity means that 
more disabled workers would be denied benefits. Even 
though the Department of Work and Pensions claims 
that the personal capacity assessment is the best assess-
ment of its type in the world, we found no scientific 
reports on its validity in Medline. Such an important test 
deserves better scientific underpinning and evaluation.
Even within Europe, disability assessment varies 
widely, with some countries relying totally on strict 
rules and others on doctors’ expertise.5 In the Nether-
lands, doctors working for insurance companies use 
a Dutch variant of the personal capacity assessment 
called the (remaining) functional abilities list.6 The 
abilities on the Dutch list are more work oriented than 
those on the UK list, and the scores for severity of 
limitations are different. For example, the most severe 
Dutch limitation is not being able to lift 1 kg compared 
with 0.5 kg in the UK. However, neither the Dutch nor 
the UK system has been properly evaluated, so we do 
not know which is best.
Surprisingly, no scientific evidence is available on 
the diagnostic accuracy of these tests and question-
naires that are used for evaluating disability. The few 
reports that exist on disability assessment are mainly 
related to sickness certification and the equipment 
used to evaluate functional capacity.7 8 This may be 
because the way society deals with disability is deeply 
embedded in culture and disability is a politically sen-
sitive matter.2 Subjecting the topic to scientific evalu-
ation might be too confrontational or politically risky 
because the results might fundamentally challenge 
current practice.
The lack of use of evidence in general in insurance 
medicine has been noted by the Dutch Health Council, 
which therefore promotes evidence based disability 
assessment and produces guidelines for doctors work-
ing for social insurance companies.9 In addition, the 
Dutch Employee Insurance Schemes Implementing 
Body has collaborated with universities to form the 
Research Centre for Insurance Medicine, with the 
intention of improving the quality of disability assess-
ment and guidance on reintegration.
Clinicians and researchers are increasingly inter-
ested in their patients’ ability to work and how to 
help them return to work, especially those with back 
pain, rheumatoid arthritis, and cancer.10 The exper-
tise they have gained should be put to better use in 
evaluating disability.
Employers have a relatively negative image of 
 people with disabilities and many are reluctant to offer 
jobs.11 Once a disabled person leaves the work force it 
is difficult for him or her to return. The Organisation 
for Economic Cooperation and Development therefore 
advises tailored intervention during the first few weeks 
of sick leave. This approach has been evaluated and 
found to be successful in the Netherlands.12 Doctors 
can therefore help their patients with disabilities the 
most by supporting them in retaining their jobs.3 
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